Shoaib Ghias

Shoaib Ghias is a partner in the firm’s Business Law Department and a member of its Technology Companies & Life Sciences group. His representation of start-up and later stage companies spans the entire corporate life cycle, including formation matters, venture capital financings, mergers and acquisitions, public offerings, SEC reporting and compliance, and general corporate representation and counseling. His clients are in the life sciences, biotechnology, medical device, software and information technology services industries. Dr. Ghias joined Goodwin in 2013 and has worked with many of his company-side clients since their initial founding.

Private Company Financings, Joint Ventures and Strategic Matters

• Tranquis Therapeutics, a biotechnology company focused on therapeutics for neurodegenerative and aging-related disease, in its $30 million Series A financing
• C4 Therapeutics, a clinical-stage biopharmaceutical company pioneering a new class of small-molecule medicines that selectively destroy disease-causing proteins, in its $73 million Series A financing and $170 million Series B financing
• Relay Therapeutics, a biopharmaceutical company focusing on drug discovery centered on protein motion, in its $400 million Series C financing
• Skyhawk Therapeutics, a biopharmaceutical company developing small molecule therapeutics that correct RNA expression, in its financings and corporate matters
• Dragonfly Therapeutics, a biopharmaceutical company developing novel immunotherapies that harness the innate immune system to treat disease, in its financings and corporate matters
• Allogene Therapeutics, a clinical-stage biotechnology company pioneering the development of allogeneic CAR T therapies for cancer, in its joint venture with Overland Pharmaceuticals
• Deerfield Catalyst, a medtech incubator committed to developing transformational solutions to improve patient outcomes and streamline care, in its formation and structuring maters
• Moderna Therapeutics, a clinical-stage biotechnology company pioneering mRNA therapeutics and vaccines, in its corporate structuring matters

IPOs, Public Company Financings and deSPAC Transactions

• C4 Therapeutics, a clinical-stage biopharmaceutical company pioneering a new class of small-molecule medicines that selectively destroy disease-causing proteins, in its $182 million IPO and $180 million follow-on offering
• The underwriters in the $84 million IPO of Rani Therapeutics, a clinical-stage biotherapeutics company focused on advancing technologies to enable the development of orally administered biologics
• Better Therapeutics, a prescription digital therapeutics company delivering cognitive behavioral therapy to address the root causes of cardiometabolic diseases, in its business combination agreement with Mountain Crest Acquisition Corp II
• Graphite Bio, a clinical-stage biotechnology company focused on therapies that harness targeted gene integration to treat or cure serious diseases, in its $273 million IPO
• Eidos Therapeutics, a clinical-stage biopharmaceutical company focused on diseases caused by transthyretin (TTR) amyloidosis (ATTR), in its $122 million IPO, $100 million ATM facility, and $25 million strategic investment from Alexion
• Zafgen, a biopharmaceutical company focusing on metabolic disorders, in its $102.7 million IPO, $129.5 million and $60 million follow-on offerings, and $50 million ATM facility
• Viveve Medical, a medical device company focused on women’s intimate health, in its $32 million follow-on offering, $25 million and $6.7 million ATM facilities, $11.5 million stock and warrant offering, and $32 million debt-to-equity conversion
• The underwriters in the $113 million IPO of Alarm.com, a cloud-based security and home automation company

Mergers and Acquisitions

• AbCellera Biologics, a technology company with a centralized operating system for next-generation antibody discovery, in its acquisition of TetraGenetics
• Zafgen, a biopharmaceutical company focusing on metabolic disorders, in its definitive merger agreement with Chondrial Therapeutics
• Ocera Therapeutics, a biopharmaceutical company developing therapeutics for liver diseases, in its sale to Mallinckrodt for $42 million in cash and up to $75 million in contingent value rights for milestone payments
• Albany Molecular Research Inc. (AMRI), a global CRMO, in its $358 million cross-border acquisition of Euticals
• Purple Carrot, a vegan meal kit delivery company, in its cross-border sale to Oisix ra daichi for $12.8 million in cash and up to $17.2 million earn-out
• NeuStar, a global information and analytics services provider, in its $2.9 billion sale to Golden Gate Capital and GIC
• Millennial Media, a mobile ad platform company, in its approximately $250 million acquisition by AOL/Verizon, and its $108 million acquisition of Nexage, an online ad reseller

Dr. Ghias holds a M.S. in Computer Science with a concentration in Bioinformatics. His master’s research was funded by the National Institute of Biomedical Imaging and Bioengineering and consisted of 3D image processing of PET and MRI data to guide neurosurgery at the Children’s Hospital of Michigan. He also holds a Ph.D. in Jurisprudence and Social Policy, focusing on comparative and international law and politics. His doctoral work has received awards or honorable mentions from the American Bar Foundation and the American Society of Comparative Law and the American Political Science Association.